June 2025 in “British Journal of Dermatology” This study detailed the implementation of an autonomous AI device in an NHS skin cancer pathway, showing that it achieved a sensitivity of 97.3% for diagnosing skin cancers and exceeded sensitivity targets compared to specialists with a negative predictive value over 99.7%.
136 citations
,
March 1996 in “Journal of the American Chemical Society” This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.
9 citations
,
August 1980 in “Journal of Cutaneous Pathology” This study found that Rhodamin B staining of keratin was inconsistent across normal skin, epithelial tumors, and dermatoses, with notable differences in staining intensity between tricho-hyalin and keratohyalin granules.
20 citations
,
February 2002 in “Expert Opinion on Therapeutic Patents” This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.
16 citations
,
January 2003 in “Nuclear Receptor Signaling” Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.